Bone Marrow Aspirate Concentrate Improves the Early Osseous Integration of Fresh Osteochondral Allografts in the Knee: A Randomized Controlled Trial.

Este estudio ha sido identificado como potencialmente de alto impacto. La métrica de alto impacto de OE, basada en la inteligencia artificial, estima la influencia que puede tener un artículo integrando señales procedentes tanto de la revista en la que se publica como del contenido científico del propio artículo. Desarrollado mediante el procesamiento del lenguaje natural más avanzado, el modelo de Alto Impacto de OE predice con mayor precisión el futuro rendimiento de las citas de un estudio que el factor de impacto de la revista por sí solo. Esto permite reconocer antes las investigaciones clínicamente significativas y ayuda a los lectores a centrarse en los artículos con más probabilidades de configurar la práctica futura.

Resumen del estudio

36 patients undergoing fresh osteochondral allograft (FOCA) transplantation for focal osteochondral lesions of the knee were randomized to receive bone marrow aspirate concentrate augmentation (BMAC) or no BMAC. The primary outcome was osseous integration assessed on computed tomography using the semiquantitative assessment computed tomography osteochondral allograft scoring system. Other outcomes included graft signal density, cleft formation, cystic changes, intra-articular fragments, International Knee Documentation Committee (IKDC) score, Kujala score, Western Ontario Meniscal Evaluation Tool (WOMET) score, and Tegner activity score. Computed tomography outcomes were assessed at 3, 6, and 12 months, while clinical outcomes were assessed at 6, 12, and 24 months. Overall, BMAC improved osseous integration at the host-graft junction at 3 months, but this advantage was no longer present at 6 or 12 months. Patient-reported outcomes were comparable between groups, suggesting that BMAC may accelerate early graft incorporation without providing superior short-term clinical outcomes.